- (1) "Acid-fast bacilli (AFB)" means bacteria that are not decolorized by acid-alcohol after having been stained with dyes such as basic fuschsin, including the mycobacteria and nocardiae.
- (2) "A country with a high TB rate" means any country except the U.S., Canada, Australia, New Zealand, countries in western and northern Europe.
- (3) "Case of tuberculosis" means an episode of tuberculosis disease meeting the clinical or laboratory criteria for tuberculosis as defined in the National Notifiable Diseases Surveillance System (NNDSS). The department incorporates by reference the Tuberculosis 2009 Case Definition, CSTE (Council of State and Territorial Epidemiologists) Position Statement, 09-ID-65.
- (4) "Department" means the Utah Department of Health and Human Services.
- (5) "Directly observed therapy" means a method of treatment in which health-care providers or other designated individuals physically observe the individual ingesting anti-tuberculosis medications.
- (6) "Drug resistant tuberculosis" means tuberculosis bacteria which is resistant to one or more anti-tuberculosis drugs.
- (7) "Multi-drug resistant tuberculosis" means tuberculosis bacteria which is resistant to at least isoniazid and rifampin.
- (8) Program" means the Utah Department of Health and Human Services, Office of Communicable Disease, TB Control Program.
- (9) "Suspect case" means an individual who is suspected to have tuberculosis disease, including a person with signs and symptoms consistent with tuberculosis, having AFB recovered from sputum or any other source with identification pending, or started on a regimen consistent with treatment for active tuberculosis disease as described in references a and b in Subsection R388-804-6(1).
- (10) "Tuberculosis" means a disease caused by Mycobacterium tuberculosis complex, including Mycobacterium tuberculosis, Mycobacterium bovis, or Mycobacterium africanum.
- (11) "Tuberculosis disease" means a state of active tuberculosis, pulmonary or extra-pulmonary, as determined by a chest radiograph, the bacteriologic examination of body tissues or secretions, other diagnostic procedures or physician diagnosis.
- (12) "Tuberculosis infection" means the presence of M. tuberculosis in the body but the absence of clinical or radiographic evidence of active disease as documented by a significant tuberculin skin test, or Interferon Gamma Release Assay (IGRA), including Quantiferon or T-SPOT, a negative chest radiograph and the absence of clinical signs and symptoms.
The definitions described in Section 26B-7-301 apply to this rule. Additionally:
KEY: tuberculosis, screening, communicable diseases
Date of Last Change: November 8, 2024
Notice of Continuation: May 7, 2026
Authorizing, and Implemented or Interpreted Law: 26B-7-206 through 26B-7-209; 26B-7-303 through 26B-7-315; 26B-7-3